ArticleFrontiers in pharmacology2022

Identification and characterization of a novel SNAT2 (SLC38A2) inhibitor reveals synergy with glucose transport inhibition in cancer cells.

Gregory Gauthier-Coles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.